CJC-1295 + Ipamorelin

Two synergistic growth hormone releasing peptides commonly combined for a more pronounced, sustained increase in circulating growth hormone.

Typical bottle: 5 mg / 5 mg

Research note: This combination is one of the most widely discussed growth-hormone-axis stacks in peptide research communities, but published human trial data for the combination specifically (versus each compound’s individual mechanism) remain limited.

What It Is

CJC-1295 and Ipamorelin are two complementary peptides commonly used together to stimulate the body’s natural production of growth hormone. CJC-1295 is a growth hormone-releasing hormone (GHRH) analog that increases the secretion and prolongs the half-life of endogenous growth hormone. Ipamorelin is a selective growth hormone secretagogue that mimics ghrelin, further enhancing GH release from the pituitary gland.

When combined, these peptides are researched for a more pronounced and sustained increase in circulating growth hormone than either compound alone, working through two different receptor pathways that converge on the same downstream effect: increased GH and, subsequently, IGF-1.

Who May Benefit

Lean muscle mass research
Joint health and recovery
Fat metabolism research
Accelerated tissue repair
Sleep quality and overnight recovery
Growth hormone axis research
Recovery from physical stress
Body composition research

What to Expect

This combination is generally researched as a longer-term protocol (12–16 weeks on, 2–4 weeks off) rather than something expected to produce an immediate change.

Elevated growth hormone levels are associated with several downstream processes — improved joint comfort, increased lean muscle mass, enhanced fat metabolism, and accelerated tissue repair — but these develop gradually and depend heavily on training, nutrition, and sleep quality alongside the protocol.

What to Pair It With

Ipamorelin

The GHRP half of this combination can also be researched on its own for a milder, more selective GH pulse.

IGF-1 LR3

Works further downstream in the same GH/IGF-1 axis, of interest when muscle growth is the primary research target.

BPC-157

Tissue repair and inflammatory regulation complement a recovery-focused GH protocol.

MOTS-C

Mitochondrial function and metabolic signaling provide a complementary cellular-energy angle.

Reconstitution

Vial

5 mg / 5 mg

Diluent

1 mL Bac. Water

Route

Subcutaneous

10 units = 500 mcg + 500 mcg20 units = 1 mg + 1 mg

Suggested Research Dosing Strategy

Provided Research Reference

500 mcg + 500 mcg – 1 mg + 1 mg

Once daily, in the PM before bed · subcutaneous, typically in the abdomen.

Suggested research cycle: 12–16 weeks ON / 2–4 weeks OFF. Estimated 8–11 bottles to complete a full cycle. If water retention occurs, the source protocol suggests lowering the dose and re-titrating slowly rather than pushing through.

Administration Notes

Subcutaneous injection into belly fat is the commonly described route.

Administer fasted — roughly 60 minutes after the last meal — per the source protocol.

If water retention develops, lower the dose and titrate back up slowly rather than continuing to escalate.

Research Considerations

The appeal of pairing CJC-1295 (GHRH pathway) with Ipamorelin (ghrelin-mimetic GHRP pathway) is that they act on different receptors but converge on the same downstream GH pulse, which is why the combination is researched more often than either compound alone.

As with other GH-axis compounds, more is not automatically better — excessive GH/IGF-1 signaling has its own downsides, so response and tolerability matter more than dose escalation.

Have a specific question about CJC-1295 + Ipamorelin? Chat with Pulse, Signal IQ’s free AI research assistant — ask about mechanisms, stacking, or how it compares to other compounds.

For research purposes only. Not approved for human use. This information is provided for educational and research purposes and is not medical advice. Signal IQ does not sell peptides.

All Peptides by Goal